Enumeral Biomedical And University of Massachusetts Medical Schooll Enter Into Research Study Agreement

Study to Obtain Blood and Tissue Samples from Subjects Being Treated With Yervoy For the Treatment of Melanoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has entered into a research study agreement with University of Massachusetts Medical School (UMMS), which includes that institution’s clinical partner, UMass Memorial Health Care, Inc. Pursuant to the study agreement, UMass Medical School will provide Enumeral with tissue samples and blood samples from subjects with melanoma who are being treated with Ipilimumab (Yervoy). Enumeral will fund the tissue collection activities, and Enumeral will have access to the samples for research-only use in in-vitro studies.

“We are very excited to partner with the University of Massachusetts Medical School and UMass Memorial Health Care in this research study. Information our platform generates in such longitudinal studies could enable us to generate insights into which immunotherapeutic strategies may be successful in patients that are not well-treated by currently marketed drugs,” said Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer.

“This collaboration will allow us to study the effects of checkpoint blockade on the immune system at single cell resolution, by analyzing blood and tumor-tissue directly from individual patients using Enumeral’s unique immunoprofiling platform. This is the basis of our translational strategy to support development of novel immunotherapeutics --- what we call our Human Approach,” added M. Isabel Chiu, Ph.D., Enumeral’s Vice President of Translational and Clinical Sciences.

Enumeral’s scientists will apply the company’s proprietary platform technology to analyze single immune cells within the patient samples. The study will be conducted under the direction of William Walsh, M.D., Clinical Associate Professor of Medicine at UMMS and principal investigator.

About Enumeral

Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.

About the University of Massachusetts Medical School

The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. UMMS attracts more than $240 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the medical school is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visit www.umassmed.edu.

Forward Looking Statements Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, Enumeral’s stock price, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include, among others, the risks that (a) Enumeral’s expectations regarding market acceptance of the Company’s business in general and the Company’s ability to penetrate the antibody discovery and development fields in particular, as well as the timing of such acceptance, (b) Enumeral’s ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies, (c) the scope, validity and enforceability of Enumeral’s and third party intellectual property rights, (d) Enumeral’s ability to raise capital when needed and on acceptable terms and conditions, (e) Enumeral’s ability to comply with governmental regulation, (f) the intensity of competition, (g) changes in the political and regulatory environment and in business and fiscal conditions in the United States and overseas and (h) general economic conditions.

More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.